HK1207109A1 - Methods and compositions for treating amyloid deposits - Google Patents
Methods and compositions for treating amyloid deposits Download PDFInfo
- Publication number
- HK1207109A1 HK1207109A1 HK15107526.1A HK15107526A HK1207109A1 HK 1207109 A1 HK1207109 A1 HK 1207109A1 HK 15107526 A HK15107526 A HK 15107526A HK 1207109 A1 HK1207109 A1 HK 1207109A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mammal
- compositions
- methods
- csf
- amyloid deposits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| US61/648,801 | 2012-05-18 | ||
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207109A1 true HK1207109A1 (en) | 2016-01-22 |
Family
ID=49584137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107526.1A HK1207109A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (enExample) |
| EP (1) | EP2850195B1 (enExample) |
| JP (2) | JP6469000B2 (enExample) |
| CN (2) | CN104540952A (enExample) |
| AU (1) | AU2013263346B2 (enExample) |
| BR (1) | BR112014028666B1 (enExample) |
| CA (1) | CA2873890C (enExample) |
| ES (1) | ES2786078T3 (enExample) |
| HK (1) | HK1207109A1 (enExample) |
| IN (1) | IN2014KN02672A (enExample) |
| RU (1) | RU2673484C2 (enExample) |
| WO (1) | WO2013172964A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102584655B1 (ko) | 2014-11-14 | 2023-10-06 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016196507A1 (en) | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| EP3307391A1 (en) * | 2015-06-12 | 2018-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| EP3444344A4 (en) * | 2016-04-14 | 2020-02-19 | TAO Health Life Pharma Co., Ltd. | AMYLOSPHEROID TYPE STRUCTURE (ASPD) AND PHARMACEUTICAL COMPOSITION |
| RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| WO2018027037A2 (en) * | 2016-08-03 | 2018-02-08 | University Of South Florida | Reelin compositions for treatment of neurological disorders |
| AU2017318717B2 (en) * | 2016-09-02 | 2024-10-24 | Spark Therapeutics, Inc. | Methods and vectors for treating CNS disorders |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| CN114761569A (zh) * | 2019-10-16 | 2022-07-15 | 康奈尔大学 | 阿尔茨海默氏病的基因疗法 |
| JP2023520002A (ja) * | 2020-03-31 | 2023-05-15 | ▲ヌオ▼貝▲タイ▼医薬科技（上海）有限公司 | 細胞内タンパク質ミスフォールディング関連疾患およびリソソーム蓄積症におけるｐｉ４ｋ阻害物質の応用 |
| CA3203006A1 (en) * | 2020-11-25 | 2022-06-02 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| US20250297279A1 (en) * | 2021-12-15 | 2025-09-25 | Genans Biotechnology Co., Ltd | Recombinant aav vectors and use thereof |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| CA2591544A1 (en) * | 2004-12-15 | 2006-06-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| MX2007013734A (es) * | 2005-05-02 | 2008-03-14 | Genzyme Corp | Terapia genica para trastornos de la medula espinal. |
| KR101470472B1 (ko) * | 2006-09-14 | 2014-12-09 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| JP2013533847A (ja) * | 2010-04-23 | 2013-08-29 | ユニバーシティ オブ マサチューセッツ | コレステロール関連障害のａａｖベースの治療 |
-
2013
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015520161A (ja) | 2015-07-16 |
| EP2850195A4 (en) | 2015-12-09 |
| CA2873890A1 (en) | 2013-11-21 |
| IN2014KN02672A (enExample) | 2015-05-08 |
| ES2786078T3 (es) | 2020-10-08 |
| JP6469000B2 (ja) | 2019-02-13 |
| RU2014151218A (ru) | 2016-07-10 |
| JP2019031564A (ja) | 2019-02-28 |
| WO2013172964A1 (en) | 2013-11-21 |
| AU2013263346A1 (en) | 2014-12-04 |
| EP2850195A1 (en) | 2015-03-25 |
| CA2873890C (en) | 2022-12-06 |
| BR112014028666A2 (pt) | 2017-06-27 |
| CN112574964A (zh) | 2021-03-30 |
| EP2850195B1 (en) | 2020-01-22 |
| US20150183850A1 (en) | 2015-07-02 |
| AU2013263346B2 (en) | 2018-08-23 |
| CN104540952A (zh) | 2015-04-22 |
| BR112014028666B1 (pt) | 2021-12-07 |
| RU2673484C2 (ru) | 2018-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207109A1 (en) | Methods and compositions for treating amyloid deposits | |
| CA2832151C (en) | Methods and compositions for treating brain diseases | |
| HK1244299A1 (zh) | 治疗肌萎缩侧索硬化(als)的组合物和方法 | |
| WO2015013148A3 (en) | Methods and compositions for treating brain diseases | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| WO2011133890A8 (en) | Cns targeting aav vectors and methods of use thereof | |
| MX2020005282A (es) | Vector para la produccion de particulas aav. | |
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| AR093355A1 (es) | Composiciones y metodos para tratar proteinopatias | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| EA201692206A1 (ru) | Векторы на основе aav для генной терапии в сетчатке и cns | |
| PH12017501436A1 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
| MX388146B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
| MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
| MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
| MX349601B (es) | Remocion de virus contaminantes de preparaciones de aav. | |
| WO2014058866A3 (en) | Treatment of amyotrophic lateral sclerosis | |
| WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
| WO2014144632A3 (en) | Human pac1 antibodies | |
| WO2013119302A3 (en) | Gh61 polypeptide variants and polynucleotides encoding same | |
| WO2013163590A3 (en) | Gh61 polypeptide variants and polynucleotides encoding same | |
| EA201691004A1 (ru) | Последовательность модифицированного эндолизина kz144 |